N/A N=8 Peripheral Sensory Input in Central Post Stroke Pain (CPSP)
Central Post Stroke Pain
Primary: Reduction in Spontaneous Pain Intensity After a Peripheral Nerve Block. — 6.5; 0.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=140 Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Breast Cancer Patient
Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale
N/A N=47 Cognitive Behavioral Therapy for Diabetic Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Numeric Rating Scale (NRS) Pain Intensity — -0.83; -0.45 units on a scale — p=0.47
N/A N=105 NEPAL (Neuromodulatory Examination of Pain and Mobility Across the Lifespan)
Musculoskeletal Pain · Pain, Chronic
Primary: Short Physical Performance Battery (SPPB) — 10.95; 10.82; 11.75 score on a scale — p=0.0561
Phase 2 N=24 Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
Spinal Cord Injuries
Primary: Brief Pain Inventory, Worst Pain — 8.9; 9.7 score on scale
Phase 3 N=44 Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Spinal Cord Injuries · Neuropathic Pain
Primary: The International Spinal Cord Injury Pain Data Set (ISCIPBDS) (Version 2.0) - Change in Average Worst Neuropathic Pain Intensity — -0.5; -0.5 points
Phase 3 N=339 Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
Multiple Sclerosis
Primary: Change in Mean Pain Due to MS NRS Score — -2.02; -1.89 units on a scale — p=0.468
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
Phase 3 N=103 An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain
Spinal Cord Diseases · Spinal Cord Injuries · Neuralgia
Primary: Number of Participants With Peripheral Edema — 5; 9; 2; 0 Participants
Phase 1 N=104 Neuropathic Pain Syndrome Patient Study (MK-0000-072)
Neuralgia, Postherpetic · Diabetic Neuropathy · Painful Small-Fiber Neuropathy
Primary: Daily Evening Patient Reported Pain Intensity Scores — 0.14; 1.57 Units on a Scale — p=0.003
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale
Phase 2 N=131 A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.70; -1.81 score on a scale
N/A N=7 Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Analgesia
Postoperative Pain
Primary: Change From Baseline of Surgical Site Pain Level (NRS) at Rest [Percentage of Baseline Pain] — 64; 100; 55; 69 percentage of baseline
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
N/A N=22 Nociceptive Pain Fiber Response
Painful Peripheral Diabetic Neuropathy
Primary: Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60 — .1; .1 nerve fibers / mm squared
Phase 2 N=40 Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy · Malignant Solid Neoplasm
Primary: Change in Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline — 147.95; 135.82; 167.96; 148.45 percentage of change in CIPN
Phase 3 N=66 A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
Multiple Sclerosis · Neuropathic Pain
Primary: Change From Baseline in the Mean Pain 0-10 Numerical Rating Scale Score at the End of Treatment (4 Weeks) — -2.7; -1.4 units on a scale — p=0.005
N/A N=11 Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain
Spinal Cord Injuries · Neuropathic Pain
Primary: Change in Pain Relief With Visual Analog (VAS) Pain Scale — 3.586; 5.494; 4.041; 5.677 score on a scale
Phase 4 N=220 Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain
Central Neuropathic Pain
Primary: Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS) — 4.8; 5.0 scores on scale — p=0.578
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
Phase 3 N=75 Neuropathic Pain Management
Diabetic Neuropathies · Polyneuropathies
Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale
N/A N=12 Combined Peripheral (BreEStim) and Central Electrical Stimulation (tDCS) for Neuropathic Pain Management - Spinal Cord Injury
Pain Management
Primary: Pain as Assessed by Visual Analogue Scale (VAS) — 6.0; 5.9; 5.4; 5.3 units on a scale
Phase 3 N=542 Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain
Neuropathic Pain
Primary: Baseline Mean Pain Score — 6.41; 6.54 units on a scale
Phase 2 N=25 A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury
Neuropathic Pain Due to Spinal Cord Injury
Primary: Mean Pain Intensity (NRS) — 5.93; 5.89 units on a scale — p=0.834
Phase 2 N=155 Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.50; -1.35 score on a scale
N/A N=16 Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
Phantom Limb Pain · Postoperative Pain · Neuroma
Primary: Average Phantom Limb Pain (PLP) Score — 4.1; 3.1; 2.2; 3.0 score on a scale
Phase 2 N=125 Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the NRS — -1.98; -1.56 score on a scale
Phase 3 N=246 A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia
Pain · Peripheral Neuropathy
Primary: Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks) — -1.36; -0.84 units on a scale…
Phase 2 N=14 MC-5A for Chemotherapy Induced Peripheral Neuropathy
Neuropathy, Paraneoplastic
Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters
Phase 3 N=240 Pregabalin Peripheral Neuropathic Pain Study
Diabetic Neuropathies · Neuralgia
Primary: Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population) — 4.63; 5.13 score on scale — p=0.049